HX 044
Alternative Names: HX-044Latest Information Update: 19 Jun 2025
At a glance
- Originator HanX Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Safety, pharmacokinetics and pharmacodynamics data from preclinical trials in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 30 Nov 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in Australia (IV, Infusion) (NCT06649708)
- 21 Oct 2024 Hanx Biopharmaceuticals plans a phase I/II trial for Solid tumours (Late-stage disease) in Australia (NCT06649708, HX044-I-01)